布地奈德合剂防治RDS早期疗效研究  

Clinical study of budesonide in the prevention of RDS

作　　者：刘东成[1] 陆妹[1] 劳庆禄[1] 李卫东[1] 何源[1] 李源斌[1] 

机构地区：[1]南方医科大学附属小榄医院儿科,广东中山528415

出　　处：《临床肺科杂志》2014年第4期597-599,共3页Journal of Clinical Pulmonary Medicine

基　　金：中山市科技计划项目自助(No 20102A106)

摘　　要：目的探讨气管内滴入不同布地奈德合剂联合经鼻持续气道正压(NCPAP)对呼吸窘迫综合征(RDS)的早期疗效差异。方法按纳入标准随机将RDS高危早产儿91例(预防RDS28例,诊断RDS治疗63例)分为观察组(气管内滴入沐舒坦-布地奈德混合剂)和对照组(气管内滴入固尔苏-布地奈德混合剂),均予NCPAP通气,比较预防病例RDS发生率和RDS治疗病例PaO2/FiO2改善情况。结果两组均无RDS新发病例;两组RDS病例治疗前及治疗后6、12 h PaO2/FiO2无差异(P>0.05),治疗后1小时观察组比对照组低(P<0.01)。结论两种布地奈德混合剂及早气管内滴入均能有效预防RDS、改善RDS肺功能,但观察组显效慢。Objective To explore the early curative effect difference of early intratracheal instillation of budesonide using different ingredients combined with nasal continuous positive airway pressure （ NCPAP ） on RDS. Methods 91 preterm infants of high risk in RDS were randomly divided into two groups （including 28 infants for preventing RDS and 63 infants of RDS）. The observation group was given intratracheal instillation of a mixture of high-dose mucosolvan and budesonide early after birth, and the control group was given intratracheal instillation of a mixture of pulmonary surfactant （PS） and budesonide early after birth. The infants in both groups were given NCPAP. The incidence of RDS and the value of PaO2/FiO2 were analyzed. Results In RDS prevention intervention, the two groups had no new RDS cases, with no significant differences （P〉0.05）. There was no significant difference in PaO2/FiO2 between the two groups （P〉0.05） before and 6 and 12 hours after the treatment, but it showed significant improvement 1 hour after the treatment （P〈0.01）. Conclusion Two different formulations of budesonide mixture can prevent and treat RDS and improve lung function in the treatment of RDS, and it should be used as early as possible.

关 键 词：布地奈德 肺表面活性物质 沐舒坦 PAO2 FIO2 呼吸窘迫综合征 

分 类 号：R722.6[医药卫生—儿科]